Supplementary tables: Systematic literature review of evidence in amyloid light-chain amyloidosis

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>Systematic literature review of evidence in </b><b>amyloid light-chain amyloidosis</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>Table S1: </b>Clinical evidence literature search: inclusion/exclusion criteria</li><li><b>Table S2: </b>HRQoL evidence literature search: inclusion/exclusion criteria</li><li><b>Table S3: </b>Economic evidence literature search: inclusion/exclusion criteria</li><li><b>Table S4: </b>Resource use/indirect costs evidence literature search: inclusion/exclusion criteria</li><li><b>Table S5: </b>Search strategy for clinical evidence review: MEDLINE and EMBASE</li><li><b>Table S6: </b>Search strategy for clinical evidence review: Cochrane Library (Ovid)</li><li><b>Table S7: </b>Search strategy for the health-related quality of life evidence review</li><li><b>Table S8: </b>Search strategy for economic evidence review</li><li><b>Table S9: </b>Search strategy for resource use and indirect costs evidence review</li><li><b>Table S10: </b>Risk of bias assessment of randomized controlled trials</li><li><b>Table S11: </b>Risk of bias assessment across observational studies (case-control studies)</li><li><b>Table S12:</b> Risk of bias assessment across observational studies (cohort studies)</li><li><b>Table S13:</b> Risk of bias assessment across HRQoL studies</li></ul><p dir="ltr"><b>Introduction: </b>Treatment of amyloid light-chain (AL) amyloidosis, a rare disease with a <5-year lifespan, remains challenging. This systematic literature review (SLR) aimed to evaluate the current evidence base in AL amyloidosis. <b>Methods: </b>Literature searches on clinical, health-related quality of life, economic and resource use evidence were conducted using the Embase, MEDLINE and Cochrane databases as well as gray literature. <b>Results: </b>This SLR yielded 84 unique studies from: five randomized controlled trials; 54 observational studies; 12 health-related quality of life studies, none with utility values; no economic evaluation studies; and 16 resource use studies, none with indirect costs. <b>Conclusion:</b> This SLR highlights a paucity of published literature relating to randomized controlled trials, utility values, economic evaluations and indirect costs in AL amyloidosis.</p>